Compare iShares Self-Driving EV and Tech (IDRV) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Self-Driving EV and Tech vs Tango Therapeutics Inc. — how do they compare? iShares Self-Driving EV and Tech trades at $32 (market cap $258.76M), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 14.5× iShares Self-Driving EV and Tech's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, iShares Self-Driving EV and Tech nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Self-Driving EV and Tech for 75 Days and Tango Therapeutics Inc. for 0 Days on average.
| IDRV | TNGX | |
|---|---|---|
Market Cap | $258.76M | $3.75B |
Volume | 39,075 | 9,619,106 |
Sector | Sector/Thematic | Health |
52-Week High | $45.48 | $32.90 |
52-Week Low | $32.18 | $7.50 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDRV trades at $32.78, up 0.43% on the day, with a bearish technical outlook as moving averages signal strong selling pressure. The stock faces headwinds from lukewarm US electric vehicle adoption despite global EV sales growth. Key support sits at $32 with resistance at $33-34 levels, while oscillators remain neutral suggesting potential consolidation.
The EV sector faces mixed signals with regulatory uncertainty and oil price volatility creating near-term challenges. Long-term prospects remain tied to global EV adoption trends, particularly in China and Europe where growth continues. Investors should weigh regulatory risks against the sector's structural growth trajectory.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
